Pomalidomide-C6-NH2 hydrochloride

Background Introduction

Pomalidomide-C6-NH2 hydrochloride is an advanced E3 ligase ligand-linker conjugate commonly used in the design and synthesis of PROTACs (Proteolysis Targeting Chimeras). Pomalidomide, a derivative of thalidomide, acts as a potent ligand for the CRBN (cereblon) E3 ubiquitin ligase complex. The attached C6-alkyl linker with a terminal amine group (NH2) provides a convenient functional handle, enabling efficient conjugation to a wide range of target-binding ligands for customizable PROTAC development.

Mechanism

Pomalidomide-C6-NH2 hydrochloride works by recruiting the CRBN E3 ubiquitin ligase when incorporated into a PROTAC molecule. The pomalidomide moiety specifically binds to the CRBN substrate recognition domain, while the C6-alkyl linker and terminal amine group allow for covalent attachment to a target protein ligand. Once the PROTAC brings the E3 ligase and the target protein into close proximity, it facilitates ubiquitination of the target protein, marking it for subsequent proteasomal degradation—thus enabling selective and catalytic protein elimination within cells.

Applications

Pomalidomide-C6-NH2 hydrochloride is widely utilized in the research and development of PROTACs for targeted protein degradation. Its versatile linker and functional group allow for rapid assembly of diverse bifunctional molecules aimed at degrading disease-relevant proteins, including oncogenic proteins, transcription factors, and kinases. This conjugate is invaluable in drug discovery, chemical biology research, and the development of next-generation therapeutics addressing previously 'undruggable' targets.